topotecan has been researched along with genz-644282 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Houghton, PJ; LaVoie, EJ; Liu, A; Liu, LF; Ruchelman, AL; Zhou, N | 1 |
Anders Kolb, E; Billups, CA; Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Lock, R; Madden, SL; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Teicher, BA; Zhang, MX | 1 |
2 other study(ies) available for topotecan and genz-644282
Article | Year |
---|---|
5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, SCID; Naphthyridines; Piperazines; Piperidines; Pyrrolidines; Structure-Activity Relationship; Transplantation, Heterologous | 2005 |
Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.
Topics: Animals; Cell Proliferation; Child; Disease-Free Survival; DNA Topoisomerases, Type I; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Naphthyridines; Neoplasms, Experimental; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |